Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Voorberg

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|June 9, 2018
Weibel-Palade Body Localized Syntaxin-3 Modulates Von Willebrand Factor Secretion From Endothelial CellsMaaike Schillemans, Ellie Karampini, Bart L van den Eshof, et al.
Journal of Thrombosis and Haemostasis : JTH|September 27, 2022
Altered Fc glycosylation of anti-HLA alloantibodies in hemato-oncological patients receiving platelet transfusionsThijs L J van Osch, Tamas Pongracz, Dionne M Geerdes, et al.
Thrombosis and Haemostasis|September 21, 2018
Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic PurpuraElien Roose, Gestur Vidarsson, Kadri Kangro, et al.
British Journal of Haematology|September 27, 2022
Platelet degranulation and bleeding phenotype in a large cohort of Von Willebrand disease patientsMaurice Swinkels, Ferdows Atiq, Petra E Bürgisser, et al.
Haematologica|March 31, 2022
Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on plateletsThijs L J Van Osch, Janita J Oosterhoff, Arthur E H Bentlage, et al.
Journal of Thrombosis and Haemostasis : JTH|November 10, 2020
Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpuraLeydi Carolina Velásquez Pereira, Elien Roose, Nuno A G Graça, et al.
Blood Advances|January 17, 2025
Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAsNoa A Linthorst, Yvonne K Jongejan, Richard J Dirven, et al.
American Journal of Respiratory and Critical Care Medicine|January 26, 2022
Epigenetic Modification of the von Willebrand Factor Promoter Drives Platelet Aggregation on the Pulmonary Endothelium in Chronic Thromboembolic Pulmonary HypertensionXue D Manz, Robert Szulcek, Xiaoke Pan, et al.
Blood|May 2, 2020
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpuraElien Roose, An-Sofie Schelpe, Edwige Tellier, et al.
Journal of Thrombosis and Haemostasis : JTH|June 2, 2022
SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disordersMarjon H Cnossen, Iris van Moort, Simone H Reitsma, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
Arteriosclerosis, Thrombosis, and Vascular Biology|June 9, 2018
Weibel-Palade Body Localized Syntaxin-3 Modulates Von Willebrand Factor Secretion From Endothelial CellsMaaike Schillemans, Ellie Karampini, Bart L van den Eshof, et al.
Journal of Thrombosis and Haemostasis : JTH|September 27, 2022
Altered Fc glycosylation of anti-HLA alloantibodies in hemato-oncological patients receiving platelet transfusionsThijs L J van Osch, Tamas Pongracz, Dionne M Geerdes, et al.
Thrombosis and Haemostasis|September 21, 2018
Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic PurpuraElien Roose, Gestur Vidarsson, Kadri Kangro, et al.
British Journal of Haematology|September 27, 2022
Platelet degranulation and bleeding phenotype in a large cohort of Von Willebrand disease patientsMaurice Swinkels, Ferdows Atiq, Petra E Bürgisser, et al.
Haematologica|March 31, 2022
Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on plateletsThijs L J Van Osch, Janita J Oosterhoff, Arthur E H Bentlage, et al.
Journal of Thrombosis and Haemostasis : JTH|November 10, 2020
Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpuraLeydi Carolina Velásquez Pereira, Elien Roose, Nuno A G Graça, et al.
Blood Advances|January 17, 2025
Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAsNoa A Linthorst, Yvonne K Jongejan, Richard J Dirven, et al.
American Journal of Respiratory and Critical Care Medicine|January 26, 2022
Epigenetic Modification of the von Willebrand Factor Promoter Drives Platelet Aggregation on the Pulmonary Endothelium in Chronic Thromboembolic Pulmonary HypertensionXue D Manz, Robert Szulcek, Xiaoke Pan, et al.
Blood|May 2, 2020
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpuraElien Roose, An-Sofie Schelpe, Edwige Tellier, et al.
Journal of Thrombosis and Haemostasis : JTH|June 2, 2022
SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disordersMarjon H Cnossen, Iris van Moort, Simone H Reitsma, et al.
Pageof 16